From Cision:



Cytokinetics, Incorporated will host an investor call to discuss the topline results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten, an investigational medicine, in patients with symptomatic obstructive hypertrophic cardiomyopathy. The conference will be webcast and can be accessed by telephone for those who register in advance. The webcast replay will also be available on the company’s website for twelve months.

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors for treating diseases in which cardiac muscle performance is compromised, such as hypertrophic cardiomyopathy. They are developing small molecule drug candidates specifically designed to impact myocardial muscle function and contractility.

The company is celebrating its 25-year history of pioneering innovation focused on muscle biology and pharmacology for diseases of muscle dysfunction and conditions of muscle weakness. Forward-Looking Statements in the press release contain forward-looking statements disclaiming any intent or obligation to update them, claiming protection of the Act. Any forward-looking statements made will speak only as of the date of the press release.



Read more: Cytokinetics to Host Investor Call on December 27 to